Psymed Ventures — Pre-Seed & Seed VC Firm ($250K–$2.0M Checks)
Psymed Ventures is a Pre-Seed, Seed venture capital firm based in New York, NY. The firm typically writes $250K–$2.0M checks and has 33 portfolio companies in our records.
- Check size
- $250K–$2.0M
- Portfolio
- 33 companies on record
- Partners
- 6 listed
- AUM
- $30M
- Stage
- Pre-Seed, Seed
- HQ
- New York, NY
Last verified: 2026-06-13
Pre-Seed, Seed
$250K – $2.0M
$30M
33+ companies
6 partners
About Psymed Ventures
Psymed Ventures is a venture capital firm headquartered in New York, NY. The firm invests in companies at the frontier of mental health and neuroscience, with a strong emphasis on psychedelic medicine.
Psymed Ventures focuses on pre-seed and seed stages. It invests in the psychedelics and mental health sectors. Typical check size ranges from $250K to $2.0M. The firm has $30M in assets under management. Cold outreach is an accepted way to approach the firm.
Investment Thesis
Psymed Ventures invests in companies at the frontier of mental health and neuroscience, with a strong emphasis on psychedelic medicine.
How Psymed Ventures invests
Psymed Ventures is a vc firm based in New York, NY. The firm invests at the Pre-Seed, Seed stages.
Psymed Ventures typically writes checks of $250K–$2.0M per investment, backed by approximately $30M in assets under management.
Psymed Ventures has backed 33 companies in our records, including AERSKA, ALTO NEUROSCIENCE, ANCILIA.
Partners & Team
Recent Activity
Investment Track Record
Psymed Ventures has recorded investments in 33 portfolio companies. These include AERSKA, ALTO NEUROSCIENCE, ANCILIA, ATAI LIFE SCIENCES, BECKLEY PSYTECH, BEXSON BIOMEDICAL, BLOOM SCIENCE, BRIGHT MINDS, Delix Therapeutics, DELIX THERAPUTICS, FREEDOM BIOSCIENCES, GILGAMESH PHARMACEUTICALS, HUMANS ANONYMOUS, IMYOO, and IRIS MEDICINE. One recorded investment is in Delix Therapeutics in the neuropsychiatry sector.
The firm is backed by a team of partners with expertise in mental and brain health, psychedelic medicine therapeutics, neuropsychiatric drug development, clinical neuroscience, neurotechnology, and biotechnology investment.
Portfolio Companies (33)
Other
AERSKA
Regenerative medicine for Alzheimer's and beyond
ALTO NEUROSCIENCE
Precision psychiatry drug development platform
ANCILIA
CRISPR for live biotherapeutics and bacterial products
ATAI LIFE SCIENCES
Neuro drug development platform with 10+ programs
BECKLEY PSYTECH
Drug development platform focused neurological and psychiatric disorders
BEXSON BIOMEDICAL
Novel ketamine formulations for pain management and mental health disorders
BLOOM SCIENCE
Microbiome therapeutics platform for neurological disease
BRIGHT MINDS
Creating the next generation of psychedelics to treat mental health and other CNS disorders
DELIX THERAPUTICS
Non-hallucinogenic versions of psychedelic compounds with favorable safety and efficacy
FREEDOM BIOSCIENCES
Next generation ketamine & psychedelic therapeutics
- •Raising at Pre-Seed, Seed? You're squarely in their sweet spot.
- •Size your ask to their typical $250K – $2.0M check.
- •cold outreach ok
- •Address your outreach to a specific partner, such as Matias Serebrinsky, General Partner.
- •A warm introduction beats a cold email. Get matched and request an intro.
Featured In
Browse More Investors
Fundraising resources
Frequently Asked Questions
See if Psymed Ventures is a match for your startup
Upload your pitch deck to see how well you match with Psymed Ventures and 10,000+ other investors.
Ask your AI assistant about this investor: connect InvestorMatch to Claude or ChatGPT
Is this your profile? Request a correction or removal